Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
Main text
Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee K-J, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MR, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Jeffrey HH. 2016. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. eLife 5:e15828. doi: 10.7554/eLife.15828.
Published 13, July 2016
Due to an oversight at the time of the manuscripts publication a number of competing interests were omitted which we would like to declare:
Carlos L Arteaga (CLA) was a consultant for Genentech in 2015 and 2016. The consulting activities were not related to the manuscript. CLA is a member of the Komen Foundation’s Scientific Advisory Board.
Amy Young, Ellen Ingalla, Jim Nonomiya, Jennifer M Giltnane, Michelle A Nannini, and Deepak Sampath: Employed by Genentech and own shares.
The competing interest for Alfonso Arrazate was incorrectly listed in the original publication as ‘Shareholders of Seragon’ and has now been corrected to ‘Employed by Genentech and own shares.’
The article has been corrected accordingly.
Article and author information
Author details
Version history
Copyright
© 2019, Joseph et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 394
- views
-
- 6
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
